Treats clinically important hypotension occurring in the setting of anesthesia. Sold as Akovaz, Ephedrine Sulfate, Corphedra, Emerphed. Every FDA application for this active ingredient: 5 branded and 18 generic.
As of Nov 16, 2026, FDA lists 23 applications for Ephedrine Sulfate (sold as Akovaz, Ephedrine Sulfate, Corphedra and others), first approved Apr 29, 2016, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Ephedrine Sulfate | Part D | $0K | -100% | 0 |
| Apr 29, 2016 | AkovazNDA 208289 · TYPE 7 | Exela Pharma | 3 | Marketed |
| Jan 27, 2017 | CorphedraNDA 208943 · New formulation or manufacturer | Ph Health | 0 | Marketed |
| Mar 1, 2017 | Ephedrine SulfateNDA 208609 · New formulation or manufacturer | Renew Pharms | 2 | Discontinued |
| Aug 23, 2017 | Ephedrine SulfateANDA 209784 | Sandoz | 2 | Marketed |
| Oct 23, 2019 | Ephedrine SulfateANDA 212932 | Amneal | 2 | Marketed |
| Apr 17, 2020 | EmerphedNDA 213407 · New formulation or manufacturer | Nexus | 2 | Marketed |
| Aug 4, 2020 | Ephedrine SulfateANDA 209646 | Fresenius Kabi USA | 1 | Marketed |
| Oct 3, 2020 | Ephedrine SulfateANDA 212649 | Dr Reddys | 1 | Marketed |
| Oct 16, 2020 | Ephedrine SulfateNDA 213994 · New formulation or manufacturer | Ph Health | 1 | Marketed |
| Dec 15, 2020 | Ephedrine SulfateANDA 214334 | Hikma | 0 | Marketed |
| Jun 14, 2021 | Ephedrine SulfateANDA 214579 | Eugia Pharma | 1 | Marketed |
| Feb 25, 2022 | Ephedrine SulfateANDA 216146 | Gland | 0 | Marketed |
| Apr 14, 2022 | Ephedrine SulfateANDA 216129 | Mankind Pharma | 0 | Marketed |
| Apr 21, 2022 | Ephedrine SulfateANDA 215825 | Xiromed | 0 | Marketed |
| Mar 9, 2023 | Ephedrine SulfateANDA 214528 | Sagent Pharms Inc | 0 | Marketed |
| May 16, 2023 | Ephedrine SulfateANDA 217276 | Zydus Pharms | 0 | Discontinued |
| Jul 18, 2024 | Ephedrine SulfateANDA 219050 | Caplin | 0 | Marketed |
| Oct 11, 2024 | Ephedrine SulfateANDA 217721 | Hikma | 0 | Marketed |
| Jan 16, 2025 | Ephedrine SulfateANDA 218211 | Gland | 0 | Marketed |
| Mar 11, 2025 | Ephedrine SulfateANDA 218271 | Fresenius Kabi USA | 0 | Marketed |
| Dec 23, 2025 | Ephedrine SulfateANDA 215593 | Civica | 0 | Discontinued |
| Mar 19, 2026 | Ephedrine SulfateANDA 219991 | Fresenius Kabi USA | 0 | Marketed |
| Jul 8, 2026 | Ephedrine SulfateANDA 216740 | Baxter Hlthcare Corp | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA